Education, Research & Positions
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy Summary Nanobody-based bispecific antibody engagers offer a promising avenue for cancer immunotherapy. These molecules combine the target specificity of nanobodies, small and stable antibody Read More